# US 2020/0206198 A1 · Cftr channel activator for use in the treatment and/or prevention of gluten sensitivity conditions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0206198 A1
- Document ID: US20200206198A1
- Status: Published application
- Kind: A1
- Application number: 16/633,582
- Filed: 2018-07-25
- Published: 2020-07-02
- Earliest claimed: 2017-07-26
- Inventors: Luigi Maiuri
- Web page: https://patentgrep.com/patent/US20200206198A1

## CPC

- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/4245: Oxadiazoles
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/415: 1,2-Diazoles
- A61K 31/47: Quinolines; Isoquinolines
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to a CFTR channel activator, or a pharmaceutical composition thereof, for use in the treatment and/or prevention of conditions of gluten sensitivity, such as a) celiac disease (CD) and/or a celiac-associated condition and/or gluten-related diseases, selected from potential celiac disease, refractory celiac disease, type 1 diabetes, autoimmune thyroiditis, or (b) non-celiac gluten sensitivity (NCGS) or irritable bowel disease.

## Claims

### Claim 1

A method of treating and/or preventing at least one intestinal and/or extra-intestinal condition of gluten sensitivity selected from celiac disease, non-celiac gluten sensitivity, potential celiac disease, refractory celiac disease, type diabetes, autoimmune thyroiditis and irritable bowel disease with a CFTR channel activator, said method comprising
administering a pharmaceutically effective amount of said CFTR channel activator to a subject in need thereof.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said activator is a CFTR potentiator or amplifier.

### Claim 3 (depends on 1)

The method CFTR channel activator for use according to claim 1, wherein said activator is a CFTR potentiator.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the CFTR potentiator is selected from N-(2,4di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4dihydroquinoline-3-carboxamide, 2-[(2-1H-indol-3-ylacetyl)-methyl-amino]-N-(4-isopropyl-phenyl)-2phenyl-acetamide (PG01,P2), 4-Methyl-2-(5-phenyl-1Hpyrazol-3-yl)-phenol, 6-(Ethyl-phenyl-sulfonyl)-4oxo-1,4-dihydro-quinoline-3-carboxylic acid 2-methoxy-benzylamide, 1-(3-chlorophenyl)5-trifluoromethyl-3-hydrobenzimidazol-2-one, 2-(2-Chloro-benzoylamino)-4,5,6,7-tetrahydro-benzo[b]thiophene-3-carboxylic acid amide, 5,7,Dihydroxy-3-(4-hydroxy-phenyl)-chroman-4-one, 1-(5-Chloro-2-hydroxy-phenyl)-5-trifluoromethyl-1,3-dihydro-indol-2-one), 4-(4-Oxo4H-benzo[h]chromen-2-yl)-pyridinium; bisulfate, 3-But-3-ynyl-5-methoxy-1-phenyl-1H-pyrazole-4-carbaldehyde, 3-(2-Benzyloxy-phenyl)-5-chloromethyl-isoxazole, 5-Nitro-2-(3-Phenylpropylamino) Benzoate, 4,6,4′-trimethylangelicin, or mixtures thereof.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the CFTR potentiator is selected from N-(2,4di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4dihydroquinoline-3-carboxamide, 5,7,Dihydroxy-3-(4-hydroxy-phenyl)-chroman-4-one, 4-Methyl-2-(5-phenyl-1H-pyrazol-3-yl)-phenol or mixtures thereof.

### Claim 6 (depends on 2)

The method according to claim 2, wherein the CFTR amplifier is PTI-428.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the functional gastrointestinal disorder is the irritable bowel syndrome (IBS).

### Claim 8 (depends on 1)

A method of treating or preventing celiac disease, non-celiac gluten sensitivity, potential celiac disease, refractory celiac disease, type diabetes, autoimmune thyroiditis with a pharmaceutical composition comprising the CFTR channel activator according to claim 1 and at least one pharmaceutically acceptable excipient, said method comprising
administering a pharmaceutically effective amount of said pharmaceutical composition to a subject in need thereof.

### Claim 9 (depends on 8)

The method according to claim 8, wherein said pharmaceutical composition is in form of small intestine-specific drug oral administration forms.
